Obexelimab Drug Asset Due Diligence Report 2026

This Obexelimab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 3

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Obexelimab can convert its Bispecific antibody profile and CD19 x CD32B biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Obexelimab (query alias: obexelimab)
Modality / target	Bispecific antibody; CD19 x CD32B; CD19 inhibitors, CD32B antagonists
Highest global status	Phase 3
Originator	Xencor, Inc.
Active developers	Zenas BioPharma LLC., Shanghai Zenas Biotechnology Co., Ltd., Xencor, Inc.

The MCP disease footprint includes Warm autoimmune hemolytic anemia, Immunoglobulin G4-Related Disease, Multiple sclerosis relapse. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05662241	Phase 3	Active, not recruiting	194	Primary outcome measure
NCT05786573	Phase 3	Active, not recruiting	134	Safety and Dose Confirmation Run-in Period (SRP)
NCT06559163	Phase 2	Recruiting	190	Primary Outcome Measure

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

OBEXELIMAB, A B CELL INHIBITOR, IN IgG4-RELATED DISEASE: RESULTS FROM THE PHASE 3 INDIGO TRIAL

Phase 3; n=194; evaluation: Positive. Reported fields: SAE = 18.6 % ; SAE = 10.3 %

Obexelimab for the Treatment of IgG4-Related Disease

Phase 3; n=194; evaluation: Positive. Reported fields: Adverse Event: Arthralgias = in 19.6% of the patients in the obexelimab group vs. 11.3% of those in the placebo group ; Adverse Event: Arthralgias = in 19.6% of the patients in the obexelimab group vs. 11.3% of those in the placebo group

Week 12 Results from MoonStone, a Phase 2 Study of Obexelimab in Relapsing Multiple Sclerosis

Phase 2; n=116; evaluation: Positive. Reported fields: GdE T1 lesions(weeks 8 and 12) = 0.23 Lesions ( 0.11 - 0.51); GdE T1 lesions(weeks 8 and 12) = 0.01 Lesions ( 0.00 - 0.06)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Obexelimab addresses Warm autoimmune hemolytic anemia, Immunoglobulin G4-Related Disease, Multiple sclerosis relapse. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Bispecific antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 5 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-09-02	Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million	Phase 3	US$75.0M upfront; US$225.0M milestones; US$300.0M stated total
2023-09-05	Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb	Phase 3	US$50.0M upfront
2021-11-21	Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor	Phase 2	US$480.0M milestones; US$480.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Methods of producing Anti-CD19 antibodies”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO